Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Teva Pharmaceutical Industries (TEVJF) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Teva Pharmaceutical Industries (TEVJF) over the last 17 years, with Q4 2025 value amounting to 6.37%.

  • Teva Pharmaceutical Industries' EBITDA Margin rose 70500.0% to 6.37% in Q4 2025 from the same period last year, while for Dec 2025 it was 12.49%, marking a year-over-year increase of 143200.0%. This contributed to the annual value of 12.5% for FY2025, which is 143300.0% up from last year.
  • Teva Pharmaceutical Industries' EBITDA Margin amounted to 6.37% in Q4 2025, which was up 70500.0% from 19.69% recorded in Q3 2025.
  • In the past 5 years, Teva Pharmaceutical Industries' EBITDA Margin registered a high of 19.69% during Q3 2025, and its lowest value of 25.54% during Q2 2022.
  • Its 5-year average for EBITDA Margin is 1.88%, with a median of 4.14% in 2021.
  • In the last 5 years, Teva Pharmaceutical Industries' EBITDA Margin soared by 1251800bps in 2021 and then crashed by -404300bps in 2022.
  • Quarter analysis of 5 years shows Teva Pharmaceutical Industries' EBITDA Margin stood at 1.9% in 2021, then tumbled by -1372bps to 24.2% in 2022, then skyrocketed by 170bps to 16.96% in 2023, then tumbled by -104bps to 0.69% in 2024, then skyrocketed by 1029bps to 6.37% in 2025.
  • Its last three reported values are 6.37% in Q4 2025, 19.69% for Q3 2025, and 10.9% during Q2 2025.